<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991691</url>
  </required_header>
  <id_info>
    <org_study_id>TabPRO I</org_study_id>
    <nct_id>NCT01991691</nct_id>
  </id_info>
  <brief_title>Tablet-based Patient Reported Outcome</brief_title>
  <official_title>Pilot Study for Tablet-based Questionnaire of Patient-reported Outcomes From Patients Undergoing Chemotherapy (TabPRO I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm feasibility study. Patients that have been diagnosed with
      carcinoma and are undergoing chemotherapy have to document chemotherapy associated side
      effects on a regular basis by means of a tablet-based online questionnaire. Goal of the study
      is to find out if patients that are undergoing chemotherapy are willing to document
      chemotherapy associated side effects by means of a tablet-based online questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Tablet-based questionnaire of PRO</measure>
    <time_frame>6 months</time_frame>
    <description>Feasibility of Tablet-based questionnaire of PRO (&gt;60% of patients answer &gt;60% of questionnaires in the time frame of study duration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Answered questionnaires per patient</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>Tablet-based reported outcome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tablet-based questionnaire</intervention_name>
    <description>tablet-based patient reported outcomes (TabPRO)</description>
    <arm_group_label>Tablet-based reported outcome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients have to be â‰¥ 18 years of age

          -  written consent form and agreement to participate in the study

          -  patients that are able to follow the study instructions and that most likely will keep
             the required study appointments

          -  patients that have a histological confirmed carcinoma and are scheduled to undergo
             adjuvant or neoadjuvant chemotherapy of 6 to 8 cycles

          -  questions about chemotherapy associated side effects are composed in german. Therefore
             the study participants must have sufficient knowledge of the german language

          -  ECOG maximal level 2

        Exclusion Criteria:

          -  patients that are younger than 18 years

          -  patients that don't agree to take part of the study

          -  patients that are not able to understand the scope, the meaning and the consequences
             of that clinical study

          -  patients that have a known or constant addiction to drugs or alcohol

          -  patients that suffer from blindness or dyslexia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mallmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University Hospital Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Evangelisches Krankenhaus Bergisch-Gladbach</name>
      <address>
        <city>Bergisch-Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007 Sep-Oct;57(5):278-300. Review.</citation>
    <PMID>17855485</PMID>
  </reference>
  <reference>
    <citation>Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997 Mar;6(2):151-8.</citation>
    <PMID>9161115</PMID>
  </reference>
  <reference>
    <citation>Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW, Stone AA, Weinfurt K. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007 Nov 10;25(32):5106-12. Review. Erratum in: J Clin Oncol. 2008 Feb 20;26(6):1018. Lad, Thomas [added].</citation>
    <PMID>17991929</PMID>
  </reference>
  <reference>
    <citation>Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007 Dec 1;25(34):5374-80.</citation>
    <PMID>18048818</PMID>
  </reference>
  <reference>
    <citation>Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology. 2000 May-Jun;9(3):203-13.</citation>
    <PMID>10871716</PMID>
  </reference>
  <reference>
    <citation>Roizen MF, Coalson D, Hayward RS, Schmittner J, Thisted RA, Apfelbaum JL, Stocking CB, Cassel CK, Pompei P, Ford DE, et al. Can patients use an automated questionnaire to define their current health status? Med Care. 1992 May;30(5 Suppl):MS74-84.</citation>
    <PMID>1583942</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2013</study_first_submitted>
  <study_first_submitted_qc>November 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>May 22, 2016</last_update_submitted>
  <last_update_submitted_qc>May 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Mallmann, MD</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Antineoplastic Agents</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

